| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Semaphorin-3A, Semaphorin III, Sema III, SEMA3A, SEMAD |
| Entrez GeneID | 10371 |
| WB Predicted band size | 88.9kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This SEMA3A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 535-566 amino acids from the Central region of human SEMA3A. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
1. **"Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination"**
*作者：Goshima Y, Ito T, et al.*
摘要：该研究探讨了SEMA3A抗体在阻断Semaphorin 3A信号通路中的作用，发现其能促进损伤后神经轴突再生，并抑制抑制性神经导向分子对神经再生的阻碍。
2. **"SEMA3A controls tumor growth by regulating macrophage infiltration and polarization in the tumor microenvironment"**
*作者：Tamagnone L, Giordano S, et al.*
摘要：研究通过抗SEMA3A抗体阻断肿瘤微环境中Semaphorin 3A的功能，发现其可减少促肿瘤M2型巨噬细胞浸润，从而抑制肿瘤血管生成和转移。
3. **"Therapeutic targeting of SEMA3A in rheumatoid arthritis via monoclonal antibody attenuates synovial inflammation"**
*作者：Catalano A, et al.*
摘要：该文献显示，使用人源化抗SEMA3A抗体可中和滑膜中过表达的Semaphorin 3A，显著减轻类风湿性关节炎模型中的炎症反应和骨侵蚀。
4. **"Anti-SEMA3A antibody ameliorates pathological angiogenesis in diabetic retinopathy"**
*作者：Joyal JS, et al.*
摘要：研究证明，通过特异性抗体抑制SEMA3A信号，可减少糖尿病小鼠视网膜异常血管生成，并恢复血管正常导向功能，提示其作为视网膜病变治疗的潜在靶点。
(注：以上文献为示例，实际引用需核对真实发表信息。)
SEMA3A (Semaphorin-3A) is a secreted glycoprotein belonging to the semaphorin family, initially identified as a key axonal guidance cue during neural development. It regulates cell migration, angiogenesis, immune response, and tumor progression by binding to receptors such as neuropilins (NRP1/2) and plexins. SEMA3A antibodies are tools designed to detect, neutralize, or modulate SEMA3A activity in research and therapeutic contexts. Structurally, SEMA3A contains a conserved Sema domain, a PSI (plexin-semaphorin-integrin) domain, and an immunoglobulin (Ig)-like domain, which are critical for receptor interaction. Dysregulation of SEMA3A is linked to neurological disorders, cancer metastasis, cardiovascular diseases, and autoimmune conditions like rheumatoid arthritis.
Antibodies targeting SEMA3A (monoclonal or polyclonal) are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to study its expression and function. Neutralizing antibodies can block SEMA3A-mediated signaling pathways, offering potential therapeutic avenues. For example, inhibiting SEMA3A has shown promise in enhancing nerve regeneration, suppressing tumor angiogenesis, or modulating immune cell activity. Conversely, agonistic antibodies may mimic SEMA3A’s repulsive signals to inhibit pathological cell migration. Challenges include ensuring specificity and minimizing off-target effects. Recent studies also explore SEMA3A antibodies as biomarkers for disease progression. Overall, SEMA3A antibodies are vital for unraveling its biological roles and advancing targeted therapies.
×
